Jubilant Ingrevia Limited has informed the Exchange about Transcript

Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsCfo Debt Reduction RoadmapOrder Pipeline DisclosedInvestor Communications View source PDF

JUBLINGREA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.8%1-day move

₹650.00

prior close

₹650.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.1-0.0-0.2-1.8-3.1-4.2-3.5-4.9-4.4-0.8-1.6——

Up moveDown movePending

AI summary

Jubilant Ingrevia reported its highest quarterly revenue in 14 quarters at Rs. 1,179 crore in Q4 FY26, up 12% YoY, driven by 10% volume growth. EBITDA was Rs. 172 crore (up 11% YoY, 26% QoQ) and PAT at Rs. 86 crore (up 17% YoY, 84% QoQ). Full-year FY26 revenue stood at Rs. 1,937 crore (+7%) and EBITDA at Rs. 510 crore (+21%). Net debt fell 11% and net debt-to-EBITDA improved to 0.99x. The company highlighted its Pinnacle Journey strategy with a pipeline of 100+ opportunities worth ~Rs. 3,500 crore and 20+ confirmed molecules with peak potential of Rs. 1,100 crore. CDMO is growing ~30-40% annually. Management guided at least 20% EBITDA growth for FY27, with capex of Rs. 400-500 crore planned and sequential growth expected from Q1 FY27.

Likely market impact

Strong execution with margin improvement and deleveraging signals confidence in sustained growth; management's 20% EBITDA growth guidance for FY27 and robust CDMO pipeline provide a constructive medium-term outlook for shareholders.